Index
Pharmacological Reviews
Volume 32
1980

Adenosine, role in control of renin release, 128
Adenosine 3’,5’-monophosphate, cyclic, role in renin release, 126
Adenylyl cyclase
dopamine-sensitive
dopamine agonists on α, sites (table), 237
inhibition by neuroleptics, 236
Adrenergic agonists, β-, role in renin release, 144
Adrenergic antagonists
α-, effect on renin release, 141
β-, role in renin release, 144
Adrenergic receptors
α-, role, in renin release, 100
labeled by 3H-neuroleptics, 256
Adrenergic receptor antagonists, α-, effects on renin release, 133
Adrenergic receptor blocking activity, α-, drugs with, 143
Adrenergic receptor blocking drugs, β-, renin release alteration by
(table), 145
Adrenoceptors, presynaptic, development of subsensitivity of, 347
Adrenoceptors, α-
presynaptic
and postsynaptic, differences between, that mediate response of
effector organ, 341
influence of neuronal uptake of norepinephrine on negative feed-
back mechanism mediated by, 345
inhibitory
and membrane Na+/K+ in norepinephrine release, 341
and regulation of noradrenergic neurotransmission, 338
presence in central nervous system, 346
significance of negative feedback mechanism mediated by, 347
Adrenoceptors, α-
3H-clonidine binding to, in rat submaxillary gland (table), 344
3H-prazosin binding to, in rat cerebral cortex membranes (table), 344
Adrenoceptors, α1- and α2-
distribution and physiological effects mediated by (table), 343
in central nervous system (fig.), 346
localisation of, by binding studies, 344
postsynaptic, in vascular smooth muscle (fig.), 343
relative orders of potency of agonists and antagonists for (table), 342
Adrenoceptors, α2 involvement in presynaptic modulation of release of
epinephrine in central nervous system, 354
Adrenoceptors, α- and β-
presynaptic, on peripheral noradrenergic
terminals (fig.), 339
Adrenoceptors, β- presynaptic facilitatory, in peripheral noradrenergic
terminals, 348
Adrenoceptorctrophic hormone, effects on renin release, 197
Agonist
3H-, inhibition of binding
to anterior pituitary (table), 285
to brain striatum (table), 251
Alkaline phosphatase, role of changes in, on vitamin D action, 67
Alzheimer’s disease, choline or lecithin administration for, 327
Amiloride, effects on renin release, 171
Androgens, effects on renin release, 189
Anesthetics, effects on renin release, 128; (table), 130
Angiotensin II, effects on renin release, 177
Angiotensin I, inhibitors of converting enzyme of, effect on renin
release, 177
Angiotensin II antagonist of, effect on renin release, 172
brief description of, 85
pharmacology of, 85
Antidiuretic hormone, effects on renin release, 119
Anti-inflammatory drugs, nonsteroidal, effect on renin release, 181
Apopomorphine
3H-, binding conditions (table), 260
pre- and postynaptic action of, 274
Appetite control, tryptophan administration for, 329
Arginine vasopressin, effects on renin release, 119
Ataxia, choline or lecithin administration for, 328
Autonomic nervous system
drugs affecting, 133
role, in renin release, 93
Barabé, J. See Regoli and Barabé, 1
Baroreceptor, intrarenal, 86
Behavioral effects of neurotransmitter precursors, 325
Bone
cells of, and their putative roles, 50
formation and mineralization, 48
formation and resorption, 48
interrelationships, 50
resorption, 49
responses, evaluation of, 51
vitamin D
actions on, unsolved questions, 66
and, 47
effects on mineralization in, 61
effects on resorption of, 64
Bradykinin
concentration-response curves (fig.), 17
concentration-response curves of, in vascular preparations containing
receptor B1 and receptor B2 (fig.), 22
des-Arg9-, structure-activity relationship of, and its derivatives, on B1
receptor system, 25
structure and biological activities of (table), 26
history, 2
[Leu-O-Me8], des-Arg9-, specificity of inhibitory action of (table), 28
-like material, concentration of, in plasma and biological fluids of
normal subjects and patients affected by various diseases
(table), 9
primary structure of, and site of action of proteolytic enzymes (fig.), 4
radioligand assays for, 34
related kinins and, pharmacology of, 1
relative potency of, in pharmacological preparations; effects of antagon-
ists (table), 22
responsiveness of isolated blood vessels to (table), 13
structure-activity relationships of its homologues, fragments, and
analogues on the B2 receptor system, 28
Brain dopamine receptors, 229
development and aging of, hyperactivity syndrome, 284
Brain serotonin synthesis and release, food consumption, plasma amino
acid levels and, relationships between (fig.), 518
Bretylium, effects on renin release, 156
363
Bromocriptine, pre- and postsynaptic action of, 275
Bumetanide, effect on renin release, 159
Butaclamol, stereoselectivity on $^3$H-ligand binding to tissues (table), 243

Calculus, role in renin release, 112
Campbell, William B. See Keeton and Campbell, 81
Carbonic anhydrase inhibitors, effects on renin release, 169
Cardiac glycosides, effects on renin release, 158
Cardiovascular system, biological actions of kinins associated with, 10
Catecholamines
  effects on renin release in vitro, 100
  endogenous, drugs that affect, 155
  increased circulating levels of, effect on renin release, 97
  neuronal, inhibitors of uptake of, 156
  presynaptic regulation of the release of, 337
Central nervous system
  $\alpha_1$- and $\alpha_2$-adrenoceptors in (fig.), 346
  $\alpha_2$-adrenoceptor involvement in presynaptic modulation of release of epinephrine in, 354
  presence of presynaptic inhibitory $\alpha_2$-adrenoceptors in, 346
Chlordiazepoxide, effects on renin release, 171
Choline
  Alzheimer’s disease, 327
  ataxia, 328
  Huntington’s disease, 327
  myasthenic syndrome, 328
  psychiatric disorders, 328
  tardive dyskinesia, 327
  Tourette’s syndrome, 328
Cholinergic antagonists, effects on renin release, 157
Clonidine
  $^3$H, binding to $\alpha_2$-adrenoceptors in rat submaxillary gland (table), 344
  effects on renin release, 134
Clozapine, effects on renin release, 171
Collagen synthesis, effect of vitamin D on, 66
Contraceptives, oral, effects on renin release, 190
Cyclic nucleotides, involvement of, in presynaptic inhibition of norepinephrine release, 340

Depression, tryptophan for, 328
Diazoxyde, effects on renin release, 195
Diuretics
  loop, effects on renin release, 159
  mercurial, effects on renin release, 169
  minor, effects on renin release, 172
  non-loop,” effects on renin release, 169
  osmotic, effect on renin release, 169

D-L-Dopa
  effects on renin release, 138
  suppression of renin release, 138
  holidays, rehypersensitization of $D_1$ transmission, 278
Dopamine
  $^3$H, binding to $D_2$ sites in calf, IC50 values (fig.), 258
  electrophysiological action, 231
  negative feedback regulation of release of, through presynaptic inhibitory dopamine receptors, 352
  neuroleptic blockade of neurophysiological action of, 232
  neuroleptics and, conformational fit between, 233
  -related compounds, structures of (fig.), 267
    -sensitive adenylyl cyclase, dopamine cogeners on $D_4$ sites (table), 237
    -sensitive sites and receptors, terminology for (fig.), 231
  structural fit with neuroleptics (Dreiding models) (fig.), 231
Dopamine agonists
  at $D_3$ receptor, structural requirements for, 267
  acting on the $D_3$ dopamine receptor, structure-activity data (figs.), 269, 270, 271
  correlation of autoreceptor actions of, with effects on $D_3$ dopamine sites (fig.), 276
  effects of, on reversal of elevated $D_3$ receptors, 283
  inhibition of prolactin release from pituitary (figs.), 286
  pre- and postsynaptic action of, 275
Dopamine autoreceptors, possible relation to binding sites for dopaminergic $^3$H-ligands, 273
Dopamine congeners on $D_3$ sites (table), 237
Dopamine hypothesis of schizophrenia, neuroleptics and, 233
Dopamine-mimetic drug action, neuroleptic blockade of, 232
Dopamine neuromones
  lesions of
    in adult rats, 274
    in immature rats, 274
    in Parkinson’s disease, 274
Dopamine receptors
  brain, 229
    development and aging of, hyperactivity syndrome, 284
  effects of lesions on (table), 264
  effect of long-term drugs on (table), 281
  $^3$H-ligands for, 239; (table), 240
    in vivo analysis of, 239
    in peripheral tissues, 275
    in pituitary and peripheral tissues, 285
    in postmortem brains of schizophrenics (table), 282
    neuroleptic action on, 232
    neuroleptic-induced dopaminergic supersensitivity and, 280
    presynaptic inhibitory
      in peripheral noradrenergic nerve endings, 349
      negative feedback regulation of release of dopamine through, 352
      renal, femoral, and brain (table), 287
      terminology for, 230
    Dopamine-sensitive adenylyl cyclase, 255
      inhibition of, by neuroleptics, 236
Dopamine sensitivity
  density of $D_3$ receptors and, relation between, 282
  $D_3$ receptors, role of estrogen, and, 283
Dopamine turnover, 232
Dopaminergic agonist $^3$H-ligands, binding properties of, 257
Dopaminergic $^3$H-ligands
  correlations between behaviour and binding of, 265
  nonstriatal tissues, receptor density (Bmax) and $K_D$ for (table), 242
  relation of dopamine autoreceptors to binding sites for, 273
  striatum, receptor density (Bmax) and $K_D$ for (table), 241
Dopaminergic $^3$H-ligand binding, effects of ions and nucleotides on, 265
Dopaminergic nerve endings, central, presynaptic receptor systems on, 353
Dopaminergic neuromones, dopaminergic supersensitivity after denervation of, 280
Dopaminergic receptors, labeled by $^3$H-neuroleptics, 256
Dopaminergic supersensitivity
  after denervation of dopamine neuromones, 280
  after neuroleptic administration, 279
  behavioural, after long-term neuroleptics, 280
  biochemical and electrophysiological aspects of, 280
  neuroleptic-induced, dopamine receptors and, 280
Epinephrine, $\alpha_1$-adrenoceptors involvement in presynaptic modulation of release of, in central nervous system, 354
Estrogens
  antiparkinsonian action of, 263
  effects on renin release, 186
Ethacrynic acid, effects on renin release, 159
Exocrine glands, biological actions of kinins in, 15
Food consumption, plasma amino acid levels, and brain serotonin synthesis and release, relationships between (fig.), 318
Furosemide, effects on renin release, 159
INDEX

Galactorrhea, neuropeptide-induced, 232
Ganglionic stimulants, effect on renin release, 157
Glucagon, effect on renin release, 199
Glucocorticoids, effect on renin release, 188
Growth hormone, effects on renin release, 198
Guanethidine, effects on renin release, 156

Hefti, F. See Wurtman et al., 315
Huntington's disease, choline or lecithin administration for, 327
Hydralazine, effects on renin release, 191
6-Hydroxydopamine, effects on renin release, 156
5-Hydroxytryptamine, effects on renin release, 125
Hyperactivity syndrome, development and aging of brain dopamine receptors, 284
Hyperprolactinemia, neuropeptide-induced, 232

Inflammation, biological actions of kinins in, 14
Insulin, effects on renin release, 200

Kallidin
concentration-response curves (fig.), 17
primary structure of, and site of action of proteolytic enzymes (fig.), 4
Kallikrein-kinin system, 3
components of, in biological fluids, 5
Kallikreins, actions of, 15
Keeton, T. Kent, and William B. Campbell. The pharmacologic alteration of renin release, 81

Kinins
action mechanism of, 34
activation of, 3
antagonists of, on B, receptor systems, 32
antagonists that block effects of, on B, receptor system (table), 27
biological actions of, 10
bradykinin and related kinins, pharmacology of, 1
cardiovascular system, regulation of, 10
exocrine glands, actions in, 15
formation and breakdown, 3
history, 1
inactivation of, 3
inflammation, role in, 14
pharmacological and metabolic features of (table), 37
pharmacological preparations, 16
potentiation of pharmacological effects produced by, 33
properties, comparison of (table), 7
receptors for, 20
receptors mediating the contractile or relaxing effects of, in isolated smooth muscle preparations (table), 21
structure-activity studies, response (table), 19
structure and biological activities of (table), 26

Langer, S. Z. Presynaptic regulation of the release of catecholamines, 337

Lecithin
Alzheimer's disease, 327
ataxia, 328
Huntington's disease, 327
myasthenic syndrome, 328
psychiatric disorders, 328
tardive dyskinesia, 327
Tourette's syndrome, 328

Lithium, effects on renin release, 180

Magnesium, effects on renin release, 116
Melamed, E. See Wurtman et al., 315
Metabolism, renal sodium, and the macula densa segment of the distal tubule, 102
Metaraminol effects on renin release, 139
Methoxamine, inhibition of renin release, 139

Methydopa, suppression of renin release, 137
Metolazone, effects on renin release, 171
Mineralocorticoids, effect on renin release, 186
Minoxidil, effects on renin release, 193
Muscarinic antagonists, effect on renin release, 158
Muscarinic receptors, presynaptic inhibitory, in peripheral noradrenergic nerve endings, 350
Myasthenic syndrome, choline or lecithin administration for, 328
Myoclonus, posthypoxic intention, tryptophan administration, 329

Nerve impulses, neuropeptide block of, 235
Neuroendocrine effects of neurotransmitter precursors, 325
Neuroleptic
early supersensitivity after single dose of, 260
- binding properties, correlates of, 244
- inhibition of binding to anterior pituitary (table), 285
- induced catalepsy and Parkinsonism, 232
- induced dopaminergic supersensitivity, dopamine receptors and, 280
- induced galactorrhea, 232
- induced hyperprolactinemia, 232
Neuroleptic action
nanomolar concentration criterion for specific, 233
nonreceptor sites of, 234
on dopamine receptors, 232
receptor sites for, 236
stereoselective, criterion of, 234

Neuroleptic block
of nerve impulses, 235
of transmitter uptake, 236
presynaptic autoreceptors and presynaptic coupling, 235
Neuroleptic blockade
dopamine-mimetic drug action, 232
neurophysiological action of dopamine, 232
Neuroleptic-serotonin receptors (S2), sites in cerebral cortex (table), 255
Neuroleptic sites of action, criteria for, 233
Neuroleptics
dopamine and, conformational fit between, 233
dopamine hypothesis of schizophrenia and, 233
deniahibition of tyrosine hydroxylase by, 236
dopaminergic supersensitivity after administration of, 279
- H-, dopaminergic, serotonergic, and adrenergic receptors labeled by, 256
sites labeled by, 250
inhibition of dopamine-sensitive adenylate cyclase by, 236
inhibition of H-neuroleptic binding to brain striatum by (table), 245
in serum, use of D, receptors for measuring, 277
long-term, behavioural dopaminergic supersensitivity after, 280
partition coefficients of (table), 234
pre- and postsynaptic action of, 275
range and average clinical dose for controlling schizophrenia (fig.), 238
sensitivities of various sites to (table), 325
spontaneous release and membrane fluidization by, 236
tardive dyskinesia, 279

Neurologic diseases
decreased number of synapses, 324
decreased transmitter release, 324

Neurons
components of positive feedback loops, 322
lacking multisynaptic feedback loops, 322
release of variable quantities of neurotransmitter per firing without engaging feedback responses, 323
subjected to sustained increases in firing frequency, physiologic situations, 323

Neurotransmission
enhanced by precursor administration, in neurodegenerative diseases (fig.), 324
precursor availability and, 322
Neurotransmitter precursor availability, 316
behavioral effects of, 325
blood-brain barrier mechanisms mediating transport of (fig.), 317
choline, 327
clinical applications of, 327
neuroendocrine effects of, 325
tryptophan, 328
tyrosine, 329
Neurotransmitter synthesis mechanisms coupling intraneuronal precursor levels to, 320
precursor control of, 315
Nicotinic antagonists, effects on renin release, 157
Noradrenergic nerve endings peripheral and central, presynaptic inhibitory opiate receptors in, 351
peripheral presynaptic facilitatory a-1-adrenoceptors in, 346
presynaptic inhibitory dopamine receptors in, 349
presynaptic inhibitory muscarinic receptors in, 350
presynaptic receptors on, 352
Noradrenergic neurotransmission presynaptic inhibition of, by prostaglandins, 351
presynaptic inhibitory a-1-adrenoceptors and regulation of, 338
Noradrenaline, neuronal uptake of, influence on negative feedback mechanism mediated by presynaptic a1-adrenoceptors, 345
Norpinephrine release cyclic nucleotides in presynaptic inhibition of, 340
membrane Na"+K" ATPase in modulation of, through presynaptic inhibitory a-1-adrenoceptors, 341

Opiate receptors, presynaptic, in peripheral and central noradrenergic nerve endings, 351

Parkinsonism

neuroleptic-induced, 232
Parkinson’s disease
D2 receptors and, 278
lesions of dopamine neurones in, 274
Parasympathetic nervous system, effects on renin release, 102
Parathyroid hormone, effects on renin release, 200
Peripheral tissues, dopamine receptors in, 285
Phenotolamine, effects on renin release, 141
Phenylalanine, effects on renin release, 139
Phenylephrine, effects on renin release, 139
Phosphodiesterase inhibitors, role in renin release, 153
Pituitary tissues, dopamine receptors in, 285
 Plasma amino acid levels, food consumption, brain serotonin synthesis and release and, relationships between (fig.), 318
Plasma renin activity, total, alteration by physiologic and pharmacologic interventions (table), 202
Plasma (serum) renin activity, measurement of, 85
Plasma (serum) renin concentration, measurement of, 85
Potassium, effects on renin release, 109
Prazosin, H+ binding to a1-adrenoceptors in rat cerebral cortex membranes (table), 344

Prazosin, effects on renin release, 143
Precursor control of neurotransmitter synthesis, 315
Progesterone, effect on renin release, 190
Prostaglandins
presynaptic inhibition of noradrenergic neurotransmission by, 351
role in control of renin release, 122
synthesis inhibitors, effect on renin release, 181
Psychiatric disorders, choline or lecithin administration for, 328

Receptor B1, de novo formation of (table), 24

role in physiopathology, 23
preparations containing (table), 24
Receptor B2 system antagonists that block effects of kinins on (table), 27
structure-activity relationship of des-Arg9-bradykinin and its derivatives, on, 25
Receptor B3, preparations containing (table), 24
Receptor B4 systems antagonists of kinins on, 32
kinins, fragments, and analogues in (table), 30
structure-activity relationship of bradykinin, its homologues, fragments, and analogues on, 28
Receptor D1 sites and D2 receptors, differences between, 261
Receptors D2 binding properties of H-ligands to, 240
density of, relation to dopamine sensitivity, 282
dopamine agonist at, structural requirements for, 267
dopamine sensitivity, role of estrogen and, 283
IC50 values on H-agonist and H-antagonist binding to (table), 240
Parkinson’s disease and, 278
reversal of elevated, effects of dopamine agonists, 283
schizophrenia and, 278
transmission, L-dopa holidays and hypersensitization of, 278
use, for measuring neuroleptics in serum, 277
Receptors D2 and D3 sites distinction between, 260
localization of, 272
Receptors
dopamine, 229
presynaptic on peripheral noradrenergic nerve endings, 352
therapeutic potential, 354
Receptor systems, presynaptic, on central dopaminergic nerve endings, 353
Regoli, D., and J. Barabé. Pharmacology of bradykinin and related kinins, 1
Renin
active, alteration by physiologic and pharmacologic interventions (table), 202
brief description, 84
inactive alteration by physiologic and pharmacologic interventions (table), 202
and its alteration by drugs, 202
Renin-angiotensin system, inhibitors of, role in experimental and clinical hypertension, 172
Renin release
alteration of, by β-adrenergic receptor blocking drugs (table), 145
anatomical relationship of granular juxtaglomerular cells, afferent arteriole, renal sympathetic nerves, and macula densa cells of the distal tubule (fig.), 84
autonomic nervous system, role of, 93
calcium, role of, 112
effects of a1-adrenergic antagonists, 141
a1-adrenergic receptor agonists, 133
adrenocorticotropic hormone, 197
amiloride, 171
androgens, 189
anesthetics, 128; (table), 130
antagonists of angiotensin II, 172
antidiuretic hormone, 119
arginine vasopressin on, 119
bromelain, 156
bunetanide, 159
carbonic anhydrase inhibitors, 169
cardiac glycosides, 158
catecholamines on, in vitro, 100
chlorthalidone, 171
cholinergic antagonists, 157
clonidine, 134
clopidamide, 171
diazoxide, 195
L-dopa, 138
estrogen, 186
ethacrynic acid, 159
furosemide, 159
ganglionic stimulants, 157
glucocorticoids, 188
growth hormone, 198
guanethidine, 156
6-hydroxydopamine, 156
increased circulating levels of catecholamines, 97
inhibitors of angiotensin I converting enzyme, 177
insulin, 200
lithium, 180
“loop” diuretics, 159
magnesium, 116
mercurial diuretics, 169
metaraminol, 139
methoxamine, 139
metolazone, 171
mineralocorticoids, 186
minor diuretics, 172
minoxidil, 193
muscarinic antagonists, 158
nicotinic antagonists, 157
non-“loop” diuretics, 169
nonsteroidal anti-inflammatory drugs (prostaglandin synthesis inhibitors), 181
oral contraceptives, 190
osmotic diuretics, 169
parathyroid hormone, 200
phenoxybenzamine, 141
phenolamine, 141
phenylephrine, 139
potassium, 109
prazosin, 143
progestine, 190
reperine, 165
serotonin (5-hydroxytryptamine), 125
sodium, 108
sodium nitroprusside, 196
somatostatin, 199
spironolactone, 171
steroids, 186
thiazides, 189
triamterene, 171
tyramine, 140
vasodilators, 191
juxtaglomerular apparatus, anatomy of, 83
pharmacologic alteration of, 81, 129
physiologic control of, 86
renal nerve stimulation, 93
role of
adenosine in control of, 128
β-adrenergic antagonists and agonists, 144
cyclic adenosine 3′,5′-monophosphate, 126
phosphodiesterase inhibitors, 153
prostaglandins in release of, 122
suppression of, by angiotensin, 117
Renin response to α-adrenergic antagonists, importance of pre- and postfunctional α-adrenergic antagonists, 143
Reperine, effects on renin release, 155

Schizophrenia
neuroleptics and the dopamine hypothesis of, 233
range and average dose of neuroleptics for control of (fig.), 238

Schizophrenics, dopamine receptors in postmortem brains of (table), 282
Seeman, Philip. Brain dopamine receptors, 229
Serotonergic receptors labeled by 3H-neuroleptics, 256
Serotonin, effects on renin release, 125
Sleep, tryptophan administration for, 329
Sodium, effects on renin release, 108
Sodium nitroprusside, effects on renin release, 196
Somatostatin, effects on renin release, 199
Spiperone binding
to brain striatum homogenate, 3H-, typical results for drug inhibition of (fig.), 257
to rat brain tissue resolution of the dopaminergic and serotonergic components of (fig.), 256
to D2 and S2 receptors, resolution of (table), 257
Spironolactone, effects on renin release, 171
Stern, Paula H. The D vitamins and bone, 47
Steroids, effect on renin release, 186
Sympathetic nervous system
drugs that affect, 155
renal nerves, stimulation of, 93
Tardive dyskinesia
choline or lecithin administration for, 327
neuroleptics and, 279
Thiazides, effect on renin release, 169
Tourette’s syndrome, choline or lecithin administration for, 328
Triamterene, effects on renin release, 171
Tryptophan
appetite control, 329
depression, 328
posthypoxic intention myoclonus, 329
sleep, 329
Tryptophan levels
brain, relationship with serum tryptophan ratio (fig.), 317
plasma, relation to dietary protein content (fig.), 317
Tryptophan metabolism, 329
Tyramine, effect on renin release, 140
Tyrosine, 329
Tyrosine hydroxylase, disinhbition of, by neuroleptics, 236
Vascular receptor, intrarenal, 86
Vasodilators, effect on renin release, 191
Vitamin D
action of, role of changes in alkaline phosphatase, 67
actions on bone, unsolved questions, 66
analog studies (table), 57, 58
analsogs, relative potencies of, on bone resorption and intestinal receptor binding (table), 59
basic structure (fig.), 52
bioisynthesis, 52
bone and, 47
dual effects of, on bone, 61
effect on
collagen synthesis, 66
mineralization in bone, 61, 66
stimulation of bone resorption, 64
function of, in the body, 67
metabolism, 52
major pathways of (fig.), 55
pharmacokinetics, 55
structural characteristics, 52
synthetic analogs, 56
Vitamin D3 metabolites, relative potencies of, on bone function in vitro (table), 62

Wurtman, R. J., F. Hefti, and E. Melamed. Precursor control of neurotransmitter synthesis, 315
<table>
<thead>
<tr>
<th>Statement of Ownership, Management and Circulation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title of Publication:</strong> Pharmacological Reviews</td>
</tr>
<tr>
<td><strong>Frequency of Issue:</strong> Quarterly</td>
</tr>
<tr>
<td><strong>Date of Filing:</strong> 3/2/1980</td>
</tr>
<tr>
<td><strong>Extent and Nature of Circulation:</strong></td>
</tr>
<tr>
<td><strong>Annual No. Copies Each Issue During Previous 12 Months:</strong> 3895</td>
</tr>
<tr>
<td><strong>Actual No. Copies of Single Issue Published Next to Date:</strong> 3845</td>
</tr>
<tr>
<td><strong>Publication Date:</strong> 3/1980</td>
</tr>
<tr>
<td><strong>Total No. Copies Printed (This Issue):</strong> 3895</td>
</tr>
<tr>
<td><strong>Publication Date:</strong> 3/1980</td>
</tr>
<tr>
<td><strong>Number Copies Published for Other Circulation:</strong> None</td>
</tr>
<tr>
<td><strong>Total Distribution (Sum of C and D):</strong> 2914</td>
</tr>
<tr>
<td><strong>Total Paid Circulation (Sum of F and K):</strong> 2897</td>
</tr>
<tr>
<td><strong>Total Paid and Nonpaid:</strong> 3144</td>
</tr>
<tr>
<td><strong>Total Other Circulation:</strong> None</td>
</tr>
<tr>
<td><strong>Grand Total:</strong> 3144</td>
</tr>
<tr>
<td>** Classified Code (U.S. Post Office Distribution Service):** 28</td>
</tr>
<tr>
<td><strong>Publisher:</strong> Williams &amp; Wilkins Co., 428 E. Preston Street, Balt., MD 21202</td>
</tr>
<tr>
<td><strong>Managing Editor:</strong> Dr. Paul L. Mussen, School of Medicine, Univ. of N. Carolina, Chapel Hill, NC 27514</td>
</tr>
<tr>
<td><strong>Subscription Price:</strong> $20.00</td>
</tr>
<tr>
<td><strong>Address for Subscription:</strong> American Society for Pharmacology and Experimental Therapeutics, 5450 Rockville Pike, Bethesda, MD 20814</td>
</tr>
</tbody>
</table>

**Statement of Ownership:**
- **Telephone:** The telephone number is provided for Federal Income Tax purposes (Check one).
- **Paid Circulation:** The paid circulation is distributed through dealers and newsstands, street vendors, and counter sales.
- **Free Circulation:** The free circulation is divided into samples, complimentary, and other free copies.
- **Total Distribution:** The total distribution is the sum of the last two columns.
- **Return from News Agents:** None
- **Return from Paid Circulation:** None
- **Return from Sales:** None

**Certification:** The statements made in this form are correct and complete.

**Signature:**

**Date:** 3/1980

**Publisher:** Williams & Wilkins Co.